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Who would have anticipated three decades ago that patent law would soon
become a hotbed of heated philosophical and political debates? The emer-
gence of the biotechnological industry turned a dry word like ‘patent’ into
an ideological shibboleth. In some quarters of society, whether you are
for or against biopatents is no less significant than it once was whether
you are for or against the private ownership of the means of production.
The question, of course, concerns in both cases a complex matter and
calls for a multilayered answer. The anthology ‘Patente am Leben?’ is an
enormously helpful reading for those who are fond of seeing such compli-
cated issues from different professional, theoretical and ideological angles.
Since only four of its fifteen contributions are in English, this publication
addresses mainly the German-reading public. The first section sets the
stage with articles by four representatives of organisations, which play
an important part in structuring this field of policy. The piece by Rein-
hard Hermann, director of the biotechnology department at the European
Patent Office, aims at convincing the laymen that biopatents are less prob-
lematic than they may imagine. In his concluding remark, he voices the
view that the agitation about biopatents typically rests on a serious over-
estimation of the significance of particular genes or genes in general for
human life. At the other end of the ideological spectrum stands the contri-
bution of Christopher Then, expert for issues of genetic engineering and
biopatents at Greenpeace. He argues for the view that patents on genes boil
down to a systematic abuse of patent law, because they grant a temporary
monopoly on the use of a discovery and not – as it should be – on the
use of an invention. Unfortunately, at many points the somewhat polem-
ical tone of the piece makes it sound like a less than reliable source of
information.
The second part of the collection is devoted to the ethical aspects of
biopatenting. Dietmar Mieth approaches the issue from a perspective of
social ethics. The main reservation of his well-informed paper concerns the
practice of patenting biological material (Stoffpatente). Like Then, Mieth
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avers that this practice is against the spirit of the patent system, which
should further technological progress but not commercial privileges. Even
more important for his stand is a metaphysical objection against the mate-
rialism of modern biology that, according to him, is reflected in the patent
system.
The contribution ‘Biopatente – eine ethische Analyse’ is extracted from
an expert report by N. Anwander, A. Bachmann, K.P. Rippe and P. Schaber
for the Swiss government. The report rejects what may be called the ‘com-
modification objection against biopatents’. This objection considers patents
on biological material to be a violation of the intrinsic value of creatures
(Wu¨rde der Kreatur), which is protected by the Swiss constitution. The
article points out that patents do not violate the intrinsic value of an indi-
vidual creature, since they refer to types and not to tokens. For instance,
it is the idea of how to produce and commercially use the oncomouse that
is legally protected; and the legal protection of the commercial use of an
idea cannot possibly violate the intrinsic value of a particular specimen.
Nevertheless, the report expresses qualms about biopatents. Like other ar-
ticles in the collection, the authors recommend that biopatents should only
be granted for procedures, not products, since genes can be discovered but
not invented. Moreover, they see the staking of private property claims
by means of biopatents as a blatant violation of the Common Heritage of
Mankind.
The third part of the anthology deals with the legal aspects of the mat-
ter. The contributions of Geertrui van Overwalles and Christine Godt point
out that biopatents tend to have a detrimental effect on the research at
universities. Godt’s article recommends a strategic approach that copes
with the trade-off between the commodification of research and the tradi-
tional communism (R. Merton) of the scientific community. In contrast,
van Overwalles joins forces with the obviously considerable number of
product claim critics.
The fourth part of the book focuses on the range and consequences of
product claims. Ingrid Schneider’s contribution gives an informative policy
analysis of the issue, whereas Henk van Belt and Bernd Nilles investigate
the consequences of the Treaty on Trade Related Aspects of Intellectual
Property (TRIPS) for global economic opportunities. Both authors arrive
at the conclusion that TRIPS in its current form is to the disadvantage of
the less developed world.
A documentation of legal texts and a glossary complement the an-
thology in a helpful way, but do not fully compensate for the absence
of an index, which is a serious flaw in an otherwise very valuable
book.
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